PMID- 24935040
OWN - NLM
STAT- MEDLINE
DCOM- 20150202
LR  - 20140617
IS  - 1746-076X (Electronic)
IS  - 1746-0751 (Linking)
VI  - 9
IP  - 3
DP  - 2014 May
TI  - Safety and feasibility of intramyocardial versus intracoronary delivery of 
      autologous cell therapy in advanced heart failure: the REGENERATE-IHD pilot 
      study.
PG  - 269-78
LID - 10.2217/rme.14.3 [doi]
AB  - AIM: This study presents an interim safety and feasibility analysis of the 
      REGENERATE-IHD randomized controlled trial, which is examining the safety and 
      efficacy of three different delivery routes of bone marrow-derived stem cells 
      (BMSCs) in patients with ischemic heart failure. METHODS & RESULTS: The first 58 
      patients recruited to the REGENERATE-IHD study are included in this interim 
      analysis (pilot). Symptomatic patients with ischemic heart failure were 
      randomized to receive subcutaneous granulocyte colony-stimulating factor or 
      saline injections only; or subcutaneous granulocyte colony-stimulating factor 
      injections followed by intracoronary or intramyocardial injections of BMSCs or 
      serum (control). No significant differences were found in terms of safety and 
      feasibility between the different delivery routes, with no significant difference 
      in procedural complications or major adverse cardiac events. There was a signal 
      towards improved heart failure symptoms in the patients treated with 
      intramyocardial injection of mobilized BMSCs. CONCLUSION: Peripheral mobilization 
      of BMSCs with or without subsequent direct myocardial delivery appears safe and 
      feasible in patients with chronic ischemic heart failure.
FAU - Mozid, Abdul
AU  - Mozid A
AD  - Department of Cardiology, London Chest Hospital, Barts Health Trust, London, E2 
      9JX, UK.
FAU - Yeo, Chia
AU  - Yeo C
FAU - Arnous, Samer
AU  - Arnous S
FAU - Ako, Emmanuel
AU  - Ako E
FAU - Saunders, Natalie
AU  - Saunders N
FAU - Locca, Didier
AU  - Locca D
FAU - Brookman, Pat
AU  - Brookman P
FAU - Archbold, R Andrew
AU  - Archbold RA
FAU - Rothman, Martin
AU  - Rothman M
FAU - Mills, Peter
AU  - Mills P
FAU - Agrawal, Samir
AU  - Agrawal S
FAU - Martin, John
AU  - Martin J
FAU - Mathur, Anthony
AU  - Mathur A
LA  - eng
GR  - Medical Research Council/United Kingdom
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Regen Med
JT  - Regenerative medicine
JID - 101278116
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Bone Marrow Transplantation/*methods
MH  - *Drug Administration Routes
MH  - Granulocyte Colony-Stimulating Factor/administration & dosage/pharmacology
MH  - *Heart
MH  - Heart Failure/*therapy
MH  - Humans
MH  - *Myocardium
MH  - Natriuretic Peptide, Brain/administration & dosage/pharmacology
MH  - Peptide Fragments/administration & dosage/pharmacology
MH  - Pilot Projects
MH  - Transplantation, Autologous
OTO - NOTNLM
OT  - autologous bone marrow-derived stem/progenitor cells
OT  - chronic ischemic heart failure
OT  - granulocyte-colony stimulating factor
OT  - intracoronary delivery
OT  - intramyocardial delivery
EDAT- 2014/06/18 06:00
MHDA- 2015/02/03 06:00
CRDT- 2014/06/18 06:00
PHST- 2014/06/18 06:00 [entrez]
PHST- 2014/06/18 06:00 [pubmed]
PHST- 2015/02/03 06:00 [medline]
AID - 10.2217/rme.14.3 [doi]
PST - ppublish
SO  - Regen Med. 2014 May;9(3):269-78. doi: 10.2217/rme.14.3.